Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | NOS2 | P35228 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 3/20 | 0.33 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451719 | 0.91 | SIGMAR1 (0.42) | SIGMAR1NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL20884949 | 0.83 | SIGMAR1 (0.44) | SIGMAR1NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL22547351 | 0.82 | SIGMAR1 (0.44) | SIGMAR1NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL24451999 | 0.74 | SIGMAR1 (0.46) | SIGMAR1NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL20883770 | 0.72 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3TACR2PRCP | |
| SCHEMBL20883773 | 0.72 | CNR1 (0.38) | SMN1; SMN2CCR5TACR2PRCPDRD2 | |
| SCHEMBL20883545 | 0.70 | TLR9 (0.44) | SLC6A4PRCPDRD2 | |
| SCHEMBL14924095 | 0.69 | HTR2A (0.43) | SLC6A2SLC6A4SLC6A3DRD2 | |
| SCHEMBL20883541 | 0.68 | TLR9 (0.48) | — | |
| SCHEMBL20884922 | 0.68 | MCOLN3 (0.39) | SIGMAR1SMN1; SMN2CCR5TACR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | SIGMAR1 4072/4885NOS3 4089/4885NOS1 3906/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | SIGMAR1 3533/4885NOS3 3564/4885NOS1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.